Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1963 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1963 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase III Diabetes / Metabolic
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
What is being tested: The study investigates a dual-agent combination therapy of elecoglipron (a GLP-1 receptor agonist) plus dapagliflozin (an SGLT2 inhibitor) versus each…
15 Jul 2026 NCT07662109
● Recruiting Phase III Oncology
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
What is being tested: The iFIT trial evaluates personalised treatment strategies for newly diagnosed myeloma patients who are ineligible for stem cell transplantation, with…
15 Jul 2026 NCT07649525
● Recruiting Phase III
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
A drug called zeleciment basivarsen was tested to see if it safely and effectively treats myotonic dystrophy type 1.
14 Jul 2026 NCT07486934
active not recruiting Phase III Oncology
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Durvalumab alone or combined with tremelimumab compared to chemotherapy for advanced bladder cancer.
14 Jul 2026 NCT02516241
● Recruiting Phase III
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
Eptinezumab reduced migraine days more than placebo in teenagers aged 12-17 with chronic migraine.
14 Jul 2026 NCT04965675
● Recruiting Phase III
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Ruxolitinib cream safely and effectively treats vitiligo in children aged 6-12 years.
14 Jul 2026 NCT06804811
active not recruiting Phase III
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
A drug injected under the skin was tested to see if it could reduce kidney damage and was safe in patients with IgA nephropathy.
14 Jul 2026 NCT05248646
● Recruiting Phase III
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
Eptinezumab reduced migraine days in children with episodic migraine.
14 Jul 2026 NCT05897320
● Recruiting Phase III Cardiology / Cardiovascular
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
What is being tested: Elecoglipron, a novel investigational drug, is being evaluated against oral semaglutide (an established GLP-1 receptor agonist) for efficacy, safety, and…
14 Jul 2026 NCT07662213
● Recruiting Phase III Oncology
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
What is being tested: Zanidatamab (a HER2-directed bispecific antibody) combined with standard chemotherapy (Cisplatin/Gemcitabine ± PD-1/L1 inhibitor) versus chemotherapy alone in advanced HER2-positive biliary…
14 Jul 2026 NCT06282575
active not recruiting Phase III Oncology
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
A new drug combination (ceralasertib plus durvalumab) tested against standard chemotherapy in advanced lung cancer patients whose disease progressed despite previous immunotherapy.
13 Jul 2026 NCT05450692
active not recruiting Phase III Oncology
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Trial comparing a new drug combination (Dato-DXd plus durvalumab) against standard chemotherapy plus pembrolizumab for triple-negative breast cancer.
13 Jul 2026 NCT06112379
active not recruiting Phase III Oncology
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Adding rilvegostomig to standard chemotherapy after biliary tract cancer surgery may improve outcomes compared to chemotherapy alone.
10 Jul 2026 NCT06109779
● Recruiting Phase III Diabetes / Metabolic
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
What is being tested: Elecoglipron, a novel therapeutic agent, is being evaluated for efficacy and safety in reducing weight in adults with obesity or…
10 Jul 2026 NCT07667803
● Recruiting Phase III Cardiology / Cardiovascular
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
What is being tested: Finerenone (a non-steroidal mineralocorticoid receptor antagonist) versus placebo in patients with heart failure and reduced ejection fraction (HFrEF) to evaluate…
10 Jul 2026 NCT06033950
active not recruiting Phase III Oncology
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
Osimertinib continuation study for cancer patients benefiting from treatment in previous trials.
09 Jul 2026 NCT05629234
active not recruiting Phase III Diabetes / Metabolic
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
Long-term safety study of dasiglucagon injections in children with congenital hyperinsulinism, following earlier trial completion. (Word count: 19)
09 Jul 2026 NCT03941236
active not recruiting Phase III
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
Patients who received OAV101 for spinal muscular atrophy are being monitored for five years to check long-term safety and effectiveness.
09 Jul 2026 NCT05335876
● Recruiting Phase III Oncology
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
What is being tested: Surovatamig (a subcutaneous monoclonal antibody) administered as consolidation therapy following initial treatment in patients with CLL/SLL, focusing on therapeutic efficacy…
09 Jul 2026 NCT07509151
active not recruiting Phase III Oncology
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
Radioactive lutetium treatment improved survival compared to hormone therapy in men with advanced prostate cancer resistant to standard hormonal treatment.
08 Jul 2026 NCT04689828
active not recruiting Phase III
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Depemokimab was compared to mepolizumab for treating difficult-to-control EGPA in adults already on standard treatment.
08 Jul 2026 NCT05263934
active not recruiting Phase III
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Trial testing two new drugs alone and combined for generalised myasthenia gravis, measuring safety, effectiveness, and how the body responds.
08 Jul 2026 NCT05070858
active not recruiting Phase III Oncology
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Trial testing if adding epcoritamab injections to standard rituximab and lenalidomide improves outcomes in adults with relapsed/refractory follicular lymphoma.
08 Jul 2026 NCT05409066
● Recruiting Phase III Oncology
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
What is being tested: Odronextamab (an experimental bispecific antibody) combined with chemotherapy versus the standard rituximab-chemotherapy regimen in treatment-naïve adult patients with diffuse large…
08 Jul 2026 NCT06091865
● Recruiting Phase III
A Study of Brenipatide in Participants With Alcohol Use Disorder
Brenipatide tested against placebo over 56 weeks to assess whether it safely reduces alcohol use in people with alcohol use disorder.
07 Jul 2026 NCT07219953
active not recruiting Phase III Oncology
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
Durvalumab added to standard BCG therapy improved outcomes compared to BCG alone in non-muscle-invasive bladder cancer.
07 Jul 2026 NCT03528694
active not recruiting Phase III
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
Emicizumab injections prevent bleeding in babies under 12 months with severe haemophilia A, with safety and effectiveness monitored over 8 years.
07 Jul 2026 NCT04431726
● Recruiting Phase III Diabetes / Metabolic
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
A trial testing whether eloralintide injection reduces knee osteoarthritis pain in overweight or obese adults over 75 weeks.
07 Jul 2026 NCT07353931
● Recruiting Phase III Gastroenterology
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn’s Disease
This trial tests a new drug called Afimkibart to treat moderate-to-severe Crohn's disease, comparing it against placebo.
06 Jul 2026 NCT06819891
● Recruiting Phase II / Phase III
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
A trial testing whether a new drug (atumelnant) safely and effectively treats congenital adrenal hyperplasia in children.
06 Jul 2026 NCT07159841
● Recruiting Phase III
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
Baxdrostat reduced blood pressure and normalised hormone levels better than placebo in primary aldosteronism patients.
06 Jul 2026 NCT07007793
active not recruiting Phase III Oncology
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Apalutamide combined with hormone therapy improved metastasis-free survival in high-risk prostate cancer patients receiving radiotherapy.
06 Jul 2026 NCT02531516
● Recruiting Phase III Rheumatology
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
Trial testing whether baricitinib is safe and effective for treating systemic juvenile idiopathic arthritis in children aged 1-18 years.
06 Jul 2026 NCT04088396
● Recruiting Phase III Cardiology / Cardiovascular
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
What is being tested: JNJ-79635322 is being directly compared with a BCMA×CD3 bispecific antibody—both novel immunotherapies designed to engage T cells against BCMA-expressing myeloma…
06 Jul 2026 NCT07258511
active not recruiting Phase III
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Trial comparing iberdomide versus lenalidomide as maintenance therapy after stem cell transplant in newly diagnosed myeloma patients.
02 Jul 2026 NCT05827016
active not recruiting Phase III Infectious Disease
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
Two-drug HIV treatment works as well as three-drug treatment, with simpler dosing and fewer side effects in treatment-naive adults.
02 Jul 2026 NCT05979311
● Recruiting Phase III Oncology
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Treatment being tested: Trastuzumab deruxtecan (T-DXd) combined with pembrolizumab compared to platinum-based chemotherapy with pembrolizumab as first-line therapy for HER2-overexpressing advanced non-squamous non-small cell…
02 Jul 2026 NCT06899126
● Recruiting Phase III Cardiology / Cardiovascular
Thromboprophylaxis in Lower Limb Immobilisation
What is being tested: The clinical and cost effectiveness of thromboprophylaxis (blood clot prevention) in patients immobilised with plaster casts or splints following injury,…
02 Jul 2026 NCT06370273
● Recruiting Phase III
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Trial testing whether atogepant tablets safely reduce migraine frequency in children and teenagers aged 6-17 years over 12 weeks.
01 Jul 2026 NCT05711394
active not recruiting Phase III
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
Gene-edited stem cell therapy significantly improves severe sickle cell disease in children who cannot tolerate standard treatment.
01 Jul 2026 NCT05329649
active not recruiting Phase III
Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9
Long-term safety and effectiveness study of oral ribitol for a rare inherited muscle weakness condition in previous trial participants.
01 Jul 2026 NCT07678775
active not recruiting Phase III Oncology
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Adding abemaciclib to standard hormone therapy may delay cancer progression in men with advanced prostate cancer.
01 Jul 2026 NCT05288166
● Recruiting Phase III Rheumatology
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn’s Disease
What is being tested: Duvakitug, a novel therapeutic agent, is undergoing Phase 3 evaluation for induction of remission in moderately to severely active Crohn's…
01 Jul 2026 NCT07184931
● Recruiting Phase III Oncology
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Treatment being tested: TDXd (trastuzumab deruxtecan) combined with chemotherapy and pembrolizumab versus standard chemotherapy plus trastuzumab and pembrolizumab as first-line therapy for metastatic HER2-positive…
01 Jul 2026 NCT06731478
● Recruiting Phase III
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
Clemizole added to standard treatment reduced seizures more than placebo in Dravet syndrome patients.
30 Jun 2026 NCT04462770
● Recruiting Phase III Women's Health
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
Long-term study evaluating Mim8, a new factor VIII replacement therapy, for preventing bleeds in haemophilia A patients with or without inhibitors.
30 Jun 2026 NCT05685238
● Recruiting Phase II / Phase III
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Trial comparing new eye injection tiespectus against standard aflibercept treatment for wet age-related macular degeneration.
30 Jun 2026 NCT07440225
● Recruiting Phase III Diabetes / Metabolic
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
What is being tested: VX-880 is an investigational infusion therapy being evaluated for safety, tolerability, and efficacy in treating Type 1 diabetes, specifically targeting…
30 Jun 2026 NCT04786262
● Recruiting Phase III Cardiology / Cardiovascular
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
What is being tested: NNC0487-0111, a novel investigational therapy, is being evaluated against placebo for safety and efficacy in patients with HFpEF or HFmrEF…
30 Jun 2026 NCT07567001
● Recruiting Phase III Oncology
Adjuvant Tebentafusp in High Risk Ocular Melanoma
Treatment being tested: Tebentafusp (a TCR-engineered T-cell therapy) as adjuvant therapy following primary treatment in patients with high-risk uveal melanoma, aiming to prevent recurrence…
30 Jun 2026 NCT06246149